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 Many neurodegenerative diseases are characterized by the presence of 
misfolded proteins and proteotoxicity. While the dysfunctional proteins may 
differ from disease to disease, the resultant neuronal stress can create debilitating 
cognitive and motor deficits. In our lab, we are working toward ways to reduce 
these symptoms in Amyotrophic Lateral Sclerosis (ALS) through experiments on 
cell, mouse, and in vitro models. Two efforts were used to reduce the 
proteotoxicity resulting from aggregation of a mutated superoxide dismutase 
(SOD1): screening for a UBE4B inhibitor and treatment with an inhibitor of Heat 
Shock Protein 90 (HSP90). An assay able to model UBE4B auto-ubiquitination in 
vitro was found to be reliable, scalable, and useful for finding potential inhibitors 
of UBE4B. Meanwhile, cellular exposure to the HSP90 inhibitor, NVP-BEP 800, 
was shown to reduce SOD aggregation, but a drug trial in mice did not show 
significant results. The UBE4B assay and mouse drug injection results have 
provided valuable information for optimizing future experiments, with the assay 
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 The themes of protein aggregation and protein misfolding are prevalent in 
neurodegenerative diseases. In amyotrophic lateral sclerosis (ALS), one of the 
most common causes of neuronal death responsible for motor deficits is the 
misfolding of mutant forms of super oxide dismuase 1 (SOD1). One mutant 
form, G93A SOD1, results in symptoms of ALS and is studied widely in ALS 
models (Pandya et al., 2013). Findings have shown that inhibiting ubiquitination 
from UBE4B (an E3/E4 ligase) and inhibiting heat shock protein (HSP) 90 result 
in less G93A SOD1 protein aggregates (Zeinab et al., 2012; Cha et al., 2013).  
 
UBE4B Molecular Mechanisms 
 UBE4B is an E3/E4 ubiquitin ligase that is part of the E1-E2-E3 
ubiquitination system (Wu and Leng, 2011). The first step of this system involves 
an E1 enzyme binding to Mg-ATP and ubquitin. Once a high-energy thioester 
bond has formed between ubiquitin and AMP-E1, the E2 conjugating enzymes 
can engage the E1 and transfer the ubiquitin to E2’s to an E3 or target proteins 
(Schulman and Wade Harper, 2009). UBE4B participates in this system by 
receiving ubiquitin from an E2 ligase and transferring it to target proteins. 
UBE4B’s ability to create multi-ubiquitin chains on target proteins because of its 
unique HFD2-homology domain (U-box) is characteristic of an E4 enzyme, a 
special type of E3 activity (Hoppe, 2005; Wu and Leng, 2011). By creating 
 2 
polyubiquitin chains on its targets, UBE4B labels proteins for 26S proteasome 
degradation (Pickart and Fushman, 2004). In the case of UBE4B, one primary 
target is p53. The E3 ligase MDM2 is required for UBE4B to poly-ubiquitinate 
p53 (Zeinab et al., 2012). Findings from our lab (data unpublished) have 
indicated that UBE4B inhibition is able to reduce aggregates of G93A SOD1 in 
HEK cells.  
 
UBE4B Variants 
 UBE4B has three variants, two of which are important in our assays. 
Transcript variant 1 (RefSeq Accession NM_001105562.2) contains exon ex7, 
while transcript variant 2 (NM_006048.4) is missing this exon. Variant 1 is 
therefore longer than variant 2, and while variant 1 is expressed briefly in 
striated muscle undergoing regeneration, variant 2 is expressed throughout the 
body, especially in the brain (2002; Mammen et al., 2011). As such, variant 2 is 
preferred for in vitro studies on ubiquitination. In our initial assays, we were 
working with a recently purified variant 1 (Boston Biochem), and as variant 2 
(Biogen) became available, we switched our assays to include that variant.  
Transcript variant 3 (XM_005263422) has two exons more than variant 2, ex7 and 
ex7a. It is the longest of the three variants, and it only expressed in striated 




HSP90 Molecular Mechanisms 
 HSP90, like UBE4B, also plays a role in the proteasome system that is 
responsible for proper handling of mutant protein aggregates. HSP90 sequesters 
heat shock factor, HSF1, a factor that activates heat shock genes like HSP70 and 
HSP40 when it is not bound by HSP90 (Voellmy, 2004). Following induction of 
this heat shock response with HSP90 inhibitors like geldanamycin, G93A SOD1 
inclusions were reduced as well, due to increased HSP70 and HSP40 levels 
(Batulan et al., 2006).  
 
Applications of Protein Inhibition 
 Establishing the basic elements of this pathway opened the door for new 
ways to implement this knowledge. Two closely related applications of this 
pathway, drug screenings and mouse drug trials, target two different proteins 
and two different stages of treatment development. Whether we are testing our 
inhibitors using in vitro ubiquitination reactions, in cells, or in mice, our 
questions are the same - Are we manipulating the pathway as desired, and does 
this generate our desired result? 
 For the UBE4B ubiquitination assay, we wanted to make sure our E1-E2-E3 
system was working, and that auto-ubiquitination of UBE4B could be isolated 
from assay noise. Furthermore, could we use this system to screen for inhibitors 
in a reliable, scalable screen? Other TR-FRET assays using the lanthascreen kits 
have shown promise in compound screening, and high-through put screening 
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using the E2 UbcH5c was shown to activate Ube4b, so in theory the assay would 
be able to accomplish our goal of an HTS for UBE4B inhibitors (2013; 2014). For 
the mouse drug trial, we wanted to make sure that the drug could inhibit SOD 
aggregation in HEK 293T cells. After the trial, we had to question whether the 
mice survived significantly longer, and was their motor behavior better with the 
drug. While both applications have a different focus in terms of the protein 
targeted, the main concept of testing a drug in various scenarios generated very 
















MATERIALS AND METHODS 
 
UBE4B Assay Reagents 
 Our assay reagents were ordered according to the TR-FRET protocols found 
in the Lanthascreen Conjugation Assay from Life Technologies (Carlsbad, CA) . 
This required Terbium-Ubiquitin and Fluorescein-Ubiquitin, also from Life 
Technologies. Also required was an E1, an E2, and ATP-Mg+2 for the reaction to 
occur. (Justification for using these enzymes). Boston Biochem (Cambridge, MA) 
supplied the E1 (His6-UBE1, E-304), E2 (GST-UbcH5c, E2-625), and the ATP-
Mg+2.  The E3 (His-UBE4B Isoform 1) was a gift from Boston Biochem, and was 
used initially in our assays. Later on, we obtained UBE4B Isoform 2 as a gift from 
Biogen. The fill-in buffer used was the “TR-FRET buffer” described in the 
protocols, composed of 50 mM Tris-HCl pH 8 and 4 mM MgCl2. In experiments 
with p53, Boston Biochem’s His6 p53 (SP-450) and GST MDM2/HDM2 (E3-202) 
were used.  
 
UBE4B Small Scale Assay Protocols 
 Initial runs of the assay were based off of the protocols described for the 
lanthascreen conjugation assay from Life Technologies. Our final concentrations 
were 1 mM ATP-Mg+2, 50 nM E1, 200 nM E2, between 12 and 200 nM of the E3, 
300 nM of Fluorescein-Ubiquitin, and 25 nM of Terbium-Ubiquitin. Initially, we 
loaded E1, E2, the ubiquitins, and UBE4B to a final volume of 20 µL in a 384 well 
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plate. Then ATP and inhibitors were added until a final volume of 30 µL, the 
plate was centrifuged briefly, and then plate reading occurred over 1 hour, 
reading once every minute. As the assay was optimized over time, various 
enzyme concentrations, incubation times, and assay volumes were tried. Our 
most current data contains a modified protocol. E1, E2, ATP, and the ubiquitins 
are incubated at room temperature for 30 minutes, while E3 and inhibitors were 
prepared separately. The E1-E2 reaction was dispersed into all the wells of a pre-
chilled plate on ice at a volume of 5 µL and allowed to cool for 10 minutes before 
adding 5 µL of the E3 reaction and 5 µL of the inhibitor reaction. Brief 
centrifugation was followed by a 1 hour plate read, with reads occurring 
between one and seven minute intervals.  
 
UBE4B Assay Instrument Settings 
 For our assays, we measured the 495 nm and 520 nm emissions after a 340 
nm excitation using a Lanthascreen TR-FRET filter cube (Biotek, PN:8040506) in a 
Biotek Synergy H1 plate reader (Winooski, VT). We used delay time of 100 µs, an 
integration time of 200 µs, a gain of 137 for both filters, and a 7 mm read height. 
Temperature was set to 25ºC. Assays were performed in black, low-volume 384-
well plates (Corning No. 3677). Pipettes used were Rainin Pipet-Lite XLS 2-20 µL 
multichannel (Columbus, OH) with Rainin RT-L10 tips,  an Eppendorf L28886C 
10-100 µL multichannel (Hamburg, Germany) with Denville Scientific 200 µL 
polypropylene tips (South Plainfield, NJ), and a 96-well Benchtop Pipettor. 
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Intraperitoneal Injections 
 Intraperitoneal (IP) injections of SOD G93A mice with NVP-BEP 800 began 
once the mice reached 60 days old. Injections were administered 
intraperitoneally twice a week for three months. NVP-BEP 800, an Heat Shock 
Protein 90 (HSP90) inhibitor (Selleck), was dissolved in DMSO to a concentration 
of 2mM for stock solutions. Mice receiving the drug were injected with 29 gauge 
insulin syringes containing 300 µl of a solution containing half NVP-BEP800 
stock solution and half of 10% 2 - hydroxypropyl - Beta- cyclodextrin (obtained 
from Sigma-Aldrich [St. Louis, MO]) dissolved in PBS. Control mice received 
300µl of a solution containing half DMSO and half 10% 2 - hydroxypropyl - Beta- 
cyclodextrin dissolved in PBS. 
 
Rotarod  
 The Rotarod machine (LE8200) was obtained from Harvard Apparatus 
(Holliston, MA). Mice were trained on the rotarod at a constant speed of 12 rpm 
for 5 minutes, three times in one day, at one hour intervals, the day prior to 
testing. Mice that fell off during training were placed back on the rod. During 
testing day, the mice were placed on the rod at an accelerating speed, from 4 rpm 
to 40 rpm, during a span of 5 minutes. As mice fell off the rod, the time was 
recorded and they were removed from the machine. Before each run, the rod and 
trip plates were wiped with 70% ethanol. The mice underwent training and 
testing once a week. Rotarod testing and training never occurred directly 
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following injections. Testing and training ended for all mice once any mouse 
could not stay on the rod for more than one second. 
 
Grip Test 
 Mice were administered the grip test using the Bioseb Grip Test (Vitrolles, 
France) machine using the slanted mesh or a rod attachment. Three strategies 
were tried. Forelimb strength was tested by lowering the mouse by its tail and 
allowing it to grasp a slanted mesh or a rod. Hindlimb strength was tested by 
grasping a rod while being pinched behind the head (Parone et al., 2013a). Total 
limb strength was tested by holding the mouse by its tail and lower until all four 
limbs were grasping the slanted mesh.  
 
Mouse Perfusion 
 At age 20 weeks, 8 mice (1 male and 3 females from the control and treated 
groups) were transcardially perfused with 4% paraformaldehyde in PBS. The 
mice were euthanized with carbon dioxide, then rinsed with normal heparanized 
saline, then flushed with about 100 mL of physiological rinse until the liver 
became pale, and then perfused with about 100 mL PFA or until tail rigidity was 
seen. The brain and spinal cord were removed, post-fixed for 24 hours, and 





 Disease endpoint was defined as the point when a mouse could not right 
itself 10 seconds after being placed on its back (Dardiotis et al., 2013). This was 
measured as the average of three successive tests Survival measured using 10 
seconds allowed to better differentiate between mice at different stages than 
measurements using 30 seconds (Parone et al., 2013b; Aggarwal et al., 2014; 

















UBE4B ASSAY RESULTS 
  
UBE4B Variant 1 Undergoes ATP-dependent Reaction In Vitro 
 
 The “Instrument Control Set Up”, as described by Life Technologies, was 
initially tried to establish a Z factor (Z’) for our assays, but troubleshooting this 
test proved too time-consuming for our particular plate-reader machine. Instead, 
we chose to run a positive and negative control reaction, complete E1-E2-E3 
reactions with and without ATP, to test whether there was a significant 
difference among these controls. Figure 1 shows a complete reaction in 15 µL 
using 200 nM of UBE4B Variant 1, measured during the first half hour, without 





520 nm signal divided by the 495 signal. Since fluorescence energy transfer 
(FRET) occurs between the terbium-ubiquitin and the fluorescein-ubiquitins that 
have randomly paired during auto-ubiquitination of UBE4B, we will get the 520 
nm signal during FRET, but only the background 495 signal when ubiquitination 
does not occur.  The terbium-ubiquitin receives 320 nm light and either transfers 
to flourescein-ubiquitin, which itself emits at 520 nm, or itself emits at 495 nm (if 
fluorescein is not in close proximity). By taking the ratio of the 520 nm emission 
to that at 495 nm, we are able to obtain a “response ratio” that accounts for slight 
differences in volume between wells and quenching effects of colored 
compounds. 
 Given that E1 is an ATP-dependent enzyme, this separation between 
reaction with and without ATP makes sense (Variant 1 was used here because it 
was the first available enzyme purified for our use. Variant 1 is expressed in 
development in muscle cells, but is not the variant commonly used in research. 
Variant 2, the isoform present in neurons and most relevant to our studies, was 
available later (Mammen et al., 2011)). 
 From this data, we can calculate a Z-factors (Z’) at any point along the 
time frame, which is displayed in Figure 2. Since Z’> 0.5 is characteristic of a 
reliable screen, our assay should be able to accurately assess ubiquitination 
changes using the response ratio in this manner. Also a measure of proper 
separation of positive and negative controls, the signal to background ratios 
(S/B) for our assay at its peak is around 6, which is within a very acceptable 
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range.   
 
UBE4B Variant 1 Shows Concentration-Sensitive Kinetic Reactions 
 In order to establish a concentration of UBE4B that would be highly 
sensitive to the effects of inhibitors, a range of concentrations were tested, from 
195 pM to 200 nM (the protocols suggested a range from 50 to 200 nM). Figure 3 
highlight a range of 50 to 200 nM. There is hardly a difference at these 
concentrations, suggesting saturation levels of UBE4B at this high nanomolar 
concentrations. In data not shown, control wells that contained the same 
concentration range of UBE4B, but without ATP, all showed the same values. 




is absent from the reaction. Figure 4 illustrates a lower concentration range, from 






Within this range, we start to see concentrations that saturate more slowly and 
contain slower reaction rates. From here, it seemed that 25 nM was one of the 
sensitive concentrations going forward, due to its sensitivity to two-fold 
decreases in concentration. 
 
E1 Undergoes ATP-Dependent Reaction In Vitro 
 The other aspect notable about Figure 3 and Figure 4 is that there is a 
consistent rise in response ratio from wells that contain everything but UBE4B (at 
0 nM UBE4B curves). This means that over one hour, a steady signal is coming 
from just E1 and E2 reactions. This could be due to the fact that E1 contains two 
ubiquitin binding pockets that are used when transferring to E2 (Schulman and 
Wade Harper, 2009). A rare cause could be contamination of E3s in the 
purification of E1 or E2s. This phenomenon was a repeatable occurrence, which 
precludes contamination from pipetting errors.  
 
Variant 2 Acts Similar to Variant 1 
 Obtaining access to Variant 2 allowed us to produce data more relevant to 
our research. As demonstrated in Figure 5, variant 2 performs similarly to 










Measuring Reaction Rate Isolates UBE4B Activity in Variant 2  
 In establishing a measure of activity and its inhibition, we chose to focus on 
the initial slope of the reaction rather than the endpoint response ratio at an 
arbitrary time point. Since inhibitors affect the rate of reaction, reaction rate 
derived from the initial slope of a kinetic reaction would be a more direct 
measure of inhibition. Looking at the past data such as that found in Figure 4, 
this type of slope changes does indeed correlate with concentration. After 
optimizing the assay to better capture this initial slope, through extended 
incubation times and assay cooling, we were able to isolate the slope of a 
sensitive concentration of UBE4B while reducing the slope of the negative control 
wells without UBE4B (Figure 6). 
    





 Five known E3 inhibitors, labeled #619-623, were tested alongside two p53 
activators, Tenovin-1 and CP31398, and NVP-BEP 800, an HSP90 inhibitor. The 
non-E3 inhibitors were used as controls. A range of concentrations was tried 
(data not shown), and 10 µM was chosen as the ideal concentration based on the 
S/B ratio. Inhibitor concentrations in this range are found other TR-FRET assays 




with reads every 7 minutes (the minimal amount of time to scan a full 384-well 
plate), kinetic data for these compounds was obtained (Figure 7). In order to 
capture the reaction rate, the window between 7 and 28 minutes was chosen 
because over this reading period the slope was most stable and representative of 
a constant reaction rate. Linear regression was used to obtain a value for the 
slope of this window (Figure 8). The slope best represents the reaction rate, and 
any compounds inhibiting UBE4B will have a decreased slope compared to 
controls. Our results demonstrate that control drugs, and some known E3 
inhibitors, show minimal effect on the slope compared to UBE4B with no 
inhibitors. No UBE4B reactions showed a near-zero slope, which further 
confirmed that the negative controls showed the absolute absence of a reaction 
rate. In data not shown, the final reaction ratios present at 1 hour showed the 
same trends seen in Figure 8, but the S/B was significantly higher. Compound 
623 shows a significant decrease in UBE4B auto-ubiquitination, and these trends 
are present in repeated assays.  
 
Assay Optimizations: 
 Assay Volume 
 Before embarking on the task of measuring a full compound library, 
changes were made to the protocols to make the assay more reliable at the small 
scale, in about 32 wells, or 2 columns in a 384 well plate. While prior reactions 
ranged in volume from 10 -30 µL,the final well volume used was changed 15 µL, 
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which made sense for the use of a range of multichannel pipettors in pipetting 
three 5 µL reactions (R) into each well: E1, E2, ATP, and Ubiquitins (R1), UBE4B 
(R2), and inhibitors (R3). Lower volumes would be more prone to error, and any 
less than three master reaction mixes would be too cumbersome and time-
sensitive. 15 µL was also small enough to cheaply run large screens while large 
enough to generate an accurate S/B ratio.  
 Read Height 
 The S/B ratio was also further optimized for read height. Automatic read 
height for our machine was set at 7.0 mm, generating an S/B ratio of 2.55. Read 
heights at 1.0, 4.0, 8.0, and 10.68 (maximum read height allowed) were also tried, 
generating S/B ratios of 1.9, 2.18, 1.9, and 1.9, respectively. 10.68 mm was 
rejected due to read signal overflow issues on some of the wells. Given the 
highest S/B ratio at 7.0 mm, this data shows manual confirmation that existing 
instrumentation settings were optimized for our assay.  
 Incubation Times 
 Another improvement came from incubation time, a factor largely 
impacting our assay. Initial runs were done with no incubation times, as we 
wanted to capture the reaction in real-time and see what happened to begin with. 
Over time, after learning about how only E1 and E2 (R1) signals behave and the 
possible of incubating the inhibitors with UBE4B (R2+R3), various incubation 
times were tried. R1 reactions were tried at 0, 30, and 45 minutes. R2+R3 
incubation was tried at 0, 30, and 60 minutes. After running through some 
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possible combinations of incubations times that generated consistent results, the 
final protocol involved a 30 minute incubation of R1 and no incubation time for 
R2+R3. R2+R3 incubation times resulted in reaction well response ratios that 
were much higher than controls.  
 Scaling 
 Assays at this small scale were excellent for optimizing various assay 
conditions unrelated to scaling up. Also, it could be performed quickly enough 
with multichannel pipettes. Control compounds were tested on this scale as well. 
Running a whole 384 plate for a compound screen, however, would require 
different conditions. Preparation time for 384 wells cannot be accomplished in a 
timely manner using just the multichannel pipettes: with three steps required for 
each well, it would take about 30 minutes of pipetting to cover a full plate for just 
the addition of the last reaction, during which the reaction rate window would 
have already passed. However, using a 96-well bench-top pipettor solves this 
issue by reducing pipetting times by a factor of 12. It also reduces errors that can 
occur between different expulsions of a multichannel pipettor. The fixed nature 
of a 96-well electronic pipettor further ensures that reactions are dispensed 






MOUSE TRIAL RESULTS 
 
Justification of NVP-BEP 800 for Mouse Trial  
 Before testing the HSP-90 inhibitor NVP-BEP 800 on G93A mice, we tested 
its ability to reduce mutant SOD aggregation on HEK 293T cells expressing G85R 
SOD. In Figure 9, the supernatant and pellet fractions demonstrate reduction of 
G85R SOD1, with both showing a correlation between drug concentration and 
G85R reduction.  
 
NVP-BEP 800 Trial with G93A Mice 
        Given NVP-BEP 800’s ability to perform well in cell assays, we decided to 
launch a drug experiment in mice using intraperitoneal (IP) injections of the 
drug. Based on previous IP injections of mice at 5 mg drug per kg of mouse, we 




The drug was dissolved in DMSO and cyclodextrin, and injected into mice 
divided into male and female groups, which were further divided into treated 
and untreated cohorts (Gad et al., 2006). We began with 3 mice in each cohort, 
but over time lost two males from each treated and untreated cohorts, resulting 
in a final count of 1 male in each cohort, and 3 females in each cohort.  
 
Treated Males and Females Show No Significant Increases in Motor Ability Over 
Controls 
        A rotarod was used to test motor ability in the G93A SOD mice. Once per 
week, mice underwent a training day consisting of 3 rounds on the rotarod at 
constant speed, and a testing day consisting of 3 rounds of accelerating speeds. 
Testing days measured the seconds each mouse could stay on the rod. By 
training at constant speeds and testing at accelerating speeds, the test limited the 
effects of learned rotarod behavior on trying to measure raw motor ability 
(Abada et al., 2013). In Figure 10 we can see that for both males and females, the 
rotarod performance of the treated cohort did not significantly differ from that of 
the untreated group.  
 
Survival Was not Significantly Different Between Treated and Untreated Cohorts 
        Mice that could not right themselves up in ten seconds after being placed on 
their back were considered at the endpoint of the disease. Survival to this disease 
endpoint was measured to try to establish drug efficacy. Comparing the males, 
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there is a three day longer survival of the treated male, but the degree to which 
drug treatment played a role in this life extension is indeterminable given the 
low sample size. The females had a larger sample size and an even greater 
difference, 7 days, between the treated and untreated group. However, in this 
trial we had not controlled for differences between litters, which can be a 
significant factor (Scott et al., 2008). There was also significant variance in the 
survival within each cohort that reduces the strength of the one-week difference 
between cohorts. 
 
Grip Tests Did Not Provide Useful Data 
        On our Bioseb Grip Test machine, a variety of strength tests were 
implemented: forelimb strength, hind limb strength, and total limb strength. 
None of these measurements provided any useful data, and were discontinued 
after some initial trials. Firstly, mice grip strength varied wildly from trial to trial. 
Secondly, much of this variability was due to inconsistencies that the 
experimenter could not control, such as mice grasping with two limbs, but then 
during pull, releasing one or both limbs and thus giving a grip strength reading 
less than what the mouse actually possessed. Lastly, mice sometimes would 
randomly pull very strongly or loosen their grip, skewing the reliability of this 
measurement even more. Despite following the best practices for these three 
measurements, none of them seemed reliable for our purposes. A better test of 












         By implementing an in vitro assay to model ubiquitination with UBE4B, I 
was able to assess a range of compounds for UBE4B-specific inhibition. Both 
isoforms of UBE4B showed concentration-dependent changes in the response 
ratio, allowing us to correlate activity with response ratio. In addition to being 
able to detect activity changes from concentration, I also detected activity 
changes from a small screen of known E3 inhibitors, one of which demonstrated 
robust knock down of UBE4B activity.  
        There is a great potential for the assay to be used in high-throughput 
screening of compound libraries in search of more UBE4B inhibitors. By taking 
advantage of the 384 well plates, the small 15 µL size of the reaction, and the 
advantages of large 96-well pipettors, we can quickly assess thousands of 
compounds in a relatively short time frame.  
        Meanwhile, the mouse drug trial gave us knowledge of what works and 
does not work for the type of trials we want to run. Though NVP-BEP 800 did 
not significantly increase mouse survival or motor ability compared to controls, 
we were able to confirm the amount of DMSO that the mice can tolerate, as well 
as the IP injection volume that G93A mice can absorb. Also, we discovered that 
these trials are more suited to females. In future drug trials, we will keep in mind 
the importance of large sample sizes that are comparing litter-matched mice to 
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